At the 2024 Boao Forum for Asia, AstraZeneca CEO Pascal Soriot shared an optimistic vision for China's economic future, calling it a 'global innovation engine' in biopharmaceuticals. 🔬 Speaking to CGTN, Soriot highlighted the Chinese mainland's 'unmatched supply chain efficiency' and its critical role in the company's worldwide strategy.
'China isn’t just a market—it’s a partner in progress,' Soriot said, noting plans to expand R&D collaborations and clinical trials in the region. 💡 With over 30 years of operations there, AstraZeneca now sources 95% of its China-sold medications locally, blending cutting-edge tech with sustainable practices.
The CEO also spotlighted China’s rapid adoption of AI in healthcare, comparing it to 'watching a sci-fi movie turn real.' 🤖 As global supply chains evolve, Soriot emphasized China’s stability and scalability as key assets for multinationals navigating uncertain times.
